Company intelligence / Profile preview

Special Product’s Line

Ownership: Private
Employees: ~300
Development stage: Commercial

Overview

No proprietary clinical results; focus is on high-quality contract manufacturing of nonsterile pharmaceutical products with GMP compliance and regulatory approvals from EMA and AIFA.

Modalities: Small molecule pharmaceuticals (oral solids)Small molecule pharmaceuticals (oral liquids)Small molecule pharmaceuticals (semisolids)Biologics / Active Pharmaceutical Ingredient production
Industry: Contract Manufacturing Organization

Drug pipeline

1 asset

fosfomycin trometamol

Commercial

Indications: Urinary tract infection

Partnerships

Top national and multinational pharmaceutical companies globally (specific partners not named publicly)

Beyond the preview

Go deeper on Special Product’s Line.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Special Product’s Line.

Explore the full profile